T. Rowe Price Associates’s Gyre Therapeutics GYRE Stock Holding History

T. Rowe Price Associates’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-12,728	Closed	-$2.46M	–	2588
2018 Q1	$2.46M	Buy	+12,728	New	+$2.37M	﹤0.01%	1525
2016 Q4	–	Sell	-219	Closed	-$30K	–	2557
2016 Q3	$30K	Hold	219	–	–	﹤0.01%	2513
2016 Q2	$37K	Hold	219	–	–	﹤0.01%	2492
2016 Q1	$41K	Buy	+219	New	+$52.8K	﹤0.01%	2477

Other funds holding GYRE

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates's GYRE Position: Q2 2018 in Review

T. Rowe Price Associates sold out of Gyre Therapeutics (GYRE) in Q2 2018, closing a stake of 12,728 shares — an estimated $2.46M sold.

T. Rowe Price Associates first reported a position in GYRE in Q1 2016 and held it in 4 quarters. The position peaked at $2.46M in Q1 2018. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

T. Rowe Price Associates reported no remaining Gyre Therapeutics position as of Q2 2018 after selling out during the quarter.
T. Rowe Price Associates sold 12,728 Gyre Therapeutics shares in Q2 2018, an estimated $2.46M.
T. Rowe Price Associates first reported a position in Gyre Therapeutics in Q1 2016 and held it in 4 quarters.
T. Rowe Price Associates's Gyre Therapeutics position peaked at $2.46M in Q1 2018.
75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on T. Rowe Price Associates's 13F filing for Q2 2018, filed 14 Aug 2018.